David Hung makes a quick, abrupt exit at Axovant after humiliating setbacks
A month after experiencing one of the most humiliating setbacks in biotech, David Hung is bowing out as CEO of Axovant $AXON.
Hung, you’ll recall …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
